HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.

AbstractPURPOSE:
Cryoablation has been proven as a less invasive, safe, and effective treatment for localized prostate cancer. We attempted to identify the predictors of biochemical recurrence after prostate cryoablation for localized prostate cancer in this study.
METHODS:
We reviewed 114 patients who underwent primary whole-gland prostate cryoablation for localized prostate cancer from October 2008 to March 2013. The perioperative parameters included age >70 years, initial prostate-specific antigen (PSA), preoperative prostate volume, Gleason score, T stage, D'Amico risk group, postoperative PSA nadir, time to PSA nadir, and PSA biochemical recurrence, defined by Phoenix definition (nadir plus 2 ng/mL). Receiver operating characteristic (ROC) analysis was used for the best cutoff value of PSA nadir for PSA biochemical recurrence. The parameters were analyzed in binary logistic regression and Kaplan-Meier analysis for PSA biochemical recurrence.
RESULTS:
A total of 31.6 % (N = 36) patients had PSA biochemical recurrence during the median follow-up of 34.87 ± 16.49 months. ROC analysis revealed that the best cutoff value for biochemical recurrence prediction was when the PSA nadir = 0.3 ng/mL. On multivariate analysis and Kaplan-Meier analysis, the D'Amico high-risk group [hazard ratio (HR) 6.552; p = 0.014], PSA nadir >0.3 ng/mL (HR 34.062; p < 0.001), and time to PSA nadir <3 months (HR 4.144; p = 0.021) were statistically significant for PSA biochemical recurrence.
CONCLUSIONS:
The D'Amico high-risk group, postoperative PSA nadir >0.3 ng/mL, and time to PSA nadir <3 months predict biochemical recurrence in primary whole-gland prostate cryoablation.
AuthorsYi Yang Liu, Po Hui Chiang, Yao Chi Chuang, Wei Ching Lee, Yuan Tso Cheng, Hung Jen Wang
JournalAnnals of surgical oncology (Ann Surg Oncol) Vol. 22 Issue 5 Pg. 1612-7 (May 2015) ISSN: 1534-4681 [Electronic] United States
PMID25287436 (Publication Type: Journal Article)
Chemical References
  • Biomarkers, Tumor
  • Prostate-Specific Antigen
Topics
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biomarkers, Tumor (blood)
  • Combined Modality Therapy
  • Cryosurgery (methods)
  • Follow-Up Studies
  • Humans
  • Male
  • Neoplasm Grading
  • Neoplasm Recurrence, Local (blood, diagnosis)
  • Neoplasm Staging
  • Postoperative Complications
  • Prognosis
  • Prostate-Specific Antigen (blood)
  • Prostatic Neoplasms (blood, pathology, surgery)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: